Sugi Predict

Sugi Predict / Compounds / SCHEMBL2588946

SCHEMBL2588946

SCHEMBL2588946

CC(O)c1cc(F)ccc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE2A O00408 1/20 0.47
▸ KCNH2 Q12809 3/20 0.43
▸ HTR2A P28223 2/20 0.43
▸ SLC6A4 P31645 2/20 0.43
▸ PSEN1 P49768 5/20 0.41
▸ PSEN2 P49810 5/20 0.41
▸ APH1B Q8WW43 5/20 0.41
▸ NCSTN Q92542 5/20 0.41
▸ APH1A Q96BI3 5/20 0.41
▸ PSENEN Q9NZ42 5/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ JAK2 O60674 4/20 0.38
▸ CES2 O00748 2/20 0.38
▸ CES1 P23141 2/20 0.38
▸ JAK1 P23458 1/20 0.36
▸ TYK2 P29597 1/20 0.36
▸ JAK3 P52333 1/20 0.36
▸ ADRB2 P07550 1/20 0.34
▸ ADRB1 P08588 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30142930 1.00 PDE2A (0.47) PDE2AKCNH2HTR2ASLC6A4PSEN1
SCHEMBL23489650 1.00 PDE2A (0.47) PDE2AKCNH2HTR2ASLC6A4PSEN1
SCHEMBL17216071 1.00 PDE2A (0.47) PDE2AKCNH2HTR2ASLC6A4PSEN1
SCHEMBL29959441 0.85 PDE2A (0.59) PDE2AKCNH2HTR2ASLC6A4PSEN1
SCHEMBL10553613 0.85 PDE2A (0.59) PDE2AKCNH2HTR2ASLC6A4PSEN1
SCHEMBL23212834 0.85 PDE2A (0.59) PDE2AKCNH2HTR2ASLC6A4PSEN1
SCHEMBL17215540 0.85 PDE2A (0.59) PDE2AKCNH2HTR2ASLC6A4PSEN1
SCHEMBL423349 0.82 KCNH2 (0.45) KCNH2HTR2ASLC6A4PSEN1PSEN2
SCHEMBL16950756 0.80 KCNH2 (0.39) PDE2AKCNH2HTR2ASLC6A4PSEN1
SCHEMBL265533 0.80 CES2 (0.52) PDE2AKCNH2HTR2ASLC6A4PSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4223753-A1 AROYL SUBSTITUTED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Genfleet Therapeutics (Shanghai) Inc. (CN) 2023-08-09 — — EP disclosed
CN-112119070-B Selective JAK2 inhibitors and uses thereof 华东理工大学 2023-02-17 — — CN disclosed
CN-115260156-A Compounds as JAK2 inhibitors and uses thereof 华东理工大学 2022-11-01 — — CN disclosed
US-20210179598-A1 SELECTIVE JAK2 INHIBITOR AND APPLICATION THEREOF EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2021-06-17 — — US disclosed
EP-3782993-A1 SELECTIVE JAK2 INHIBITOR AND APPLICATION THEREOF East China University of Science and Technology (CN) 2021-02-24 — — EP disclosed
CN-112119070-A Selective JAK2 inhibitor and application thereof 华东理工大学 2020-12-22 — — CN disclosed
EP-3360869-B1 HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND USEFUL FOR THE TREATMENT OF DISEASES CAUSED BY LPA. UBE INDUSTRIES (JP) 2020-07-29 — — EP disclosed
CN-107698555-B Halogen-substituted heterocyclic compounds 宇部兴产株式会社 2020-05-05 — — CN disclosed
US-10597375-B2 Halogen-substituted heterocyclic compound UBE INDUSTRIES, LTD. (JP) 2020-03-24 — — US disclosed
WO-2019196937-A1 SELECTIVE JAK2 INHIBITOR AND APPLICATION THEREOF 华东理工大学 2019-10-17 — — WO disclosed
US-10000463-B2 Halogen-substituted heterocyclic compound UBE INDUSTRIES, LTD. (JP) 2018-06-19 — — US disclosed
EP-2940013-B1 HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND UBE INDUSTRIES (JP) 2018-02-21 — — EP disclosed
US-20150376160-A1 HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND UBE INDUSTRIES, LTD. (JP) 2015-12-31 — — US disclosed
EP-2940013-A1 HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND UBE Industries, Ltd. (JP) 2015-11-04 — — EP disclosed
EP-2940013-A1 HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND UBE Industries, Ltd. (JP) 2015-11-04 — — EP disclosed
US-8916593-B2 Alkoxy-substituted 2-aminopyridines as ALK inhibitors PFIZER INC. (US) 2014-12-23 — — US disclosed
WO-2014104372-A1 HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND 宇部興産株式会社 (JP) 2014-07-03 — — WO disclosed
US-20130196952-A1 HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES PFIZER INC. (US) 2013-08-01 — — US disclosed
EP-2566858-A2 HETEROCYCLIC DERIVATIVES AS ALK INHIBITORS Pfizer Inc. (US) 2013-03-13 — — EP disclosed
WO-2011138751-A2 HETEROCYCLIC DERIVATIVES AS ALK INHIBITORS PFIZER INC. (US) 2011-11-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210179598-A1 SELECTIVE JAK2 INHIBITOR AND APPLICATION THEREOF JAK2, JAK1, JAK3 PDE2A 3394/4885KCNH2 4551/4885HTR2A 3881/4885
US-20150376160-A1 HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND LPAR3, LPAR1, LPAR2 PDE2A 423/4885KCNH2 811/4885HTR2A 765/4885
US-10000463-B2 Halogen-substituted heterocyclic compound LPAR1, LPAR4, LPAR2 PDE2A 760/4885KCNH2 1120/4885HTR2A 409/4885
US-10597375-B2 Halogen-substituted heterocyclic compound LPAR3, LPAR1, LPAR2 PDE2A 423/4885KCNH2 811/4885HTR2A 765/4885
US-20130196952-A1 HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES ALK, ETV6, ACVR1 PDE2A 3778/4885KCNH2 2700/4885HTR2A 4615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.